Keros Therapeutics, Inc. - Common Stock (KROS)
CUSIP: 492327101
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 19,711,307
- Total 13F shares
- 20,068,368
- Share change
- -15,029,057
- Total reported value
- $408,413,646
- Put/Call ratio
- 44%
- Price per share
- $20.36
- Number of holders
- 161
- Value change
- -$274,881,622
- Number of buys
- 77
- Number of sells
- 97
Quarterly Holders Quick Answers
What is CUSIP 492327101?
CUSIP 492327101 identifies KROS - Keros Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 492327101:
Top shareholders of KROS - Keros Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC |
13F
3/4/5
|
Company · 10%+ Owner |
27%
|
5,389,264
|
$85,258,156 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
14%
|
2,718,777
|
$43,011,052 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
14%
|
2,717,153
|
$42,985,352 | — | 30 Sep 2025 | |
| Madison Avenue Partners, LP |
13F
13D/G
|
Company · Madison Avenue International LP |
2.7%
from 13D/G
|
2,708,218
|
$42,844,009 | — | 30 Sep 2025 | |
| Western Standard LLC |
13F
|
Company |
11%
|
2,189,882
|
$34,643,933 | — | 30 Sep 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
7.2%
|
1,418,984
|
$22,448,327 | — | 30 Sep 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
6.8%
|
1,331,425
|
$21,063,144 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
6.7%
|
1,325,483
|
$20,969,141 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
6.6%
|
1,302,978
|
$20,613,112 | — | 30 Sep 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
6.3%
|
1,233,189
|
$19,509,050 | — | 30 Sep 2025 | |
| ORBIMED ADVISORS LLC |
13F
3/4/5
|
Company · Director |
0.23%
from 3/4/5
|
1,018,734
|
$16,116,372 | — | 30 Sep 2025 | |
| ALKEON CAPITAL MANAGEMENT LLC |
13D/G
13F
|
Company |
2.7%
|
1,101,000
|
$15,645,210 | $0 | 31 Dec 2024 | |
| D. E. SHAW & CO, L.P. |
13D/G
|
— |
3.9%
|
756,156
|
$14,745,042 | -$15,400,944 | 31 Dec 2025 | |
| Logos Global Management LP |
13F
|
Company |
4.3%
|
850,000
|
$13,447,000 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
4.2%
|
837,363
|
$13,249,727 | — | 30 Sep 2025 | |
| FMR LLC |
13D/G
13F
|
Company |
1.7%
|
704,472
|
$10,010,547 | $0 | 31 Jan 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
3.1%
|
607,089
|
$9,604,148 | — | 30 Sep 2025 | |
| Redmile Group, LLC |
13F
|
Company |
2.8%
|
552,506
|
$8,740,645 | — | 30 Sep 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
2.6%
|
514,160
|
$8,134,011 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
2%
|
395,103
|
$6,250,537 | — | 30 Sep 2025 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
1.7%
|
335,154
|
$5,302,136 | — | 30 Sep 2025 | |
| PDT Partners, LLC |
13F
|
Company |
1.7%
|
332,815
|
$5,265,133 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
1.7%
|
332,758
|
$5,264,231 | — | 30 Sep 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
1.5%
|
303,122
|
$4,795,390 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
1.5%
|
292,006
|
$4,619,535 | — | 30 Sep 2025 | |
| Jennifer Lachey |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
103,855
mixed-class rows
|
$4,307,079 | — | 15 Jul 2022 | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP |
13F
|
Company |
1.3%
|
258,754
|
$4,093,488 | — | 30 Sep 2025 | |
| Rangeley Capital, LLC |
13F
|
Company |
1.3%
|
258,619
|
$4,091,353 | — | 30 Sep 2025 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
1.3%
|
257,518
|
$4,073,935 | — | 30 Sep 2025 | |
| CANADA PENSION PLAN INVESTMENT BOARD |
13F
|
Company |
1.2%
|
227,300
|
$3,595,886 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.1%
|
226,127
|
$3,577,330 | — | 30 Sep 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
1.1%
|
216,700
|
$3,428,194 | — | 30 Sep 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
1%
|
204,351
|
$3,232,833 | — | 30 Sep 2025 | |
| Man Group plc |
13F
|
Company |
0.98%
|
192,854
|
$3,050,950 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.89%
|
176,144
|
$2,786,598 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
13D/G
|
Company |
0.2%
from 13D/G
|
171,941
|
$2,720,107 | — | 30 Sep 2025 | |
| Christopher Rovaldi |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
60,000
|
$2,640,600 | — | 18 Feb 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.82%
|
162,455
|
$2,570,038 | — | 30 Sep 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.78%
|
154,700
|
$2,447,354 | — | 30 Sep 2025 | |
| RBF Capital, LLC |
13F
|
Company |
0.76%
|
150,000
|
$2,373,000 | — | 30 Sep 2025 | |
| Ran Nussbaum |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
165,762
mixed-class rows
|
$2,241,983 | — | 04 Jun 2025 | |
| Tomer Kariv |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
165,762
mixed-class rows
|
$2,241,983 | — | 04 Jun 2025 | |
| Yung H. Chyung |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
154,000
mixed-class rows
|
$1,936,440 | — | 18 Feb 2025 | |
| Julius Knowles |
3/4/5
|
Director |
—
mixed-class rows
|
119,174
mixed-class rows
|
$1,927,352 | — | 21 Nov 2025 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.62%
|
121,530
|
$1,922,605 | — | 30 Sep 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.61%
|
120,433
|
$1,905,250 | — | 30 Sep 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.56%
|
110,882
|
$1,754,153 | — | 30 Sep 2025 | |
| MONIMUS CAPITAL MANAGEMENT, LP |
13F
|
Company |
0.55%
|
108,051
|
$1,709,367 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.53%
|
103,864
|
$1,643,128 | — | 30 Sep 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.51%
|
100,141
|
$1,584,231 | — | 30 Sep 2025 |
Institutional Holders of Keros Therapeutics, Inc. - Common Stock (KROS) as of Q4 2025
As of 31 Dec 2025,
Keros Therapeutics, Inc. - Common Stock (KROS) was held by
161 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,068,368 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP, STATE STREET CORP, Madison Avenue Partners, LP, ORBIMED ADVISORS LLC, Qube Research & Technologies Ltd, JACOBS LEVY EQUITY MANAGEMENT, INC, D. E. Shaw & Co., Inc., and FEDERATED HERMES, INC..
This page lists
161
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
151
Q4 2025 holders
161
Holder diff
10
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.